At least 14 million children are expected to face disruptions to essential nutrition support and services in 2025 because of ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology ...

ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

BioAtla Inc (BCAB) reports promising clinical progress and strategic initiatives, despite facing financial constraints and operational challenges.

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

The Kentucky Attorney General’s Office on Thursday announced more than $19.8 million was awarded to 75 Kentucky organizations ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated ...